Gilead Sciences, a leader in developing innovative oral medicines targeting PI3K Delta with a focus on B-cell malignancies, including NHL and CLL uses solutions like this to describe the PI3K pathway in a format that is easy to convey and understand while being visually compelling. Only a portion of the overall image is shown here due to space constraints. Created in Illustrator with finishing touches in Photoshop.
Keywords: Color, Design, Line with Color, Advertising / Marketing, Education, Allergy / Immunology, Biotechnology, Disease Management, Molecular Biology, Pharmacology
© 2011, Gilead Science